CAR-T cells targeting BCMA/CD19 for autoimmune diseases
Part of Bones, joints & muscles, Eyes & vision, Immune system & allergy, Mouth & dental, Skin clinical trials.
This trial tests a new treatment called CAR-T cells that target two proteins (BCMA and CD19) on immune cells. It is for people with certain autoimmune diseases that have not improved with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an autoimmune disease like lupus, scleroderma, Sjogren's syndrome, or other listed conditions.
- Your standard treatments have stopped working or are not an option for you.
- You are expected to live at least 3 more months.
- Your heart, lungs, liver, and kidneys are working well enough (based on tests).
- You are not pregnant or planning to become pregnant for 2 years after the treatment.
- You have not had CAR-T therapy or another gene therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
This trial tests a new type of CAR T cell therapy for people with active lupus that has not responded to other treatments. It uses specially engineered cells to target and eliminate certain immune cells that are causing the disease, with the goal of reducing symptoms and preventing flare-ups.
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
This study tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like rheumatoid arthritis, lupus, dermatomyositis, and scleroderma that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and eliminate the B cells that are causing your autoimmune disease.
This trial tests a personalized cell therapy (CAR-T cells that target CD19 and BCMA proteins) for people with lupus, Sjogren's, scleroderma, dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, rheumatoid arthritis, or ANCA-associated vasculitis that has not responded to standard treatments. The goal is to see if this therapy can reduce disease activity.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.